Article Text

Download PDFPDF
Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with acute, uncomplicated rhinosinusitis lasting ⩾7 days, what is the relative effectiveness of mometasone furoate nasal spray, amoxicillin, and placebo?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★☆☆ Respirology ★★★★★☆☆


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:

blinded (patients and healthcare providers).*

Embedded ImageFollow up period:

up to 29 days.

Embedded ImageSetting:

71 medical centres in 14 countries.

Embedded ImagePatients:

981 patients ⩾12 years of age (mean age 35 y, 66% women) with signs and symptoms of acute rhinosinusitis for ⩾7 days but ⩽28 days and major symptom score (MSS) ⩾5 but ⩽12, with ⩽3 of 5 symptoms rated as severe (based on the sum of scores for rhinorrhoea, postnasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness).

Embedded ImageIntervention:

mometasone furoate nasal spray, 200 μg, once daily for 15 days (n = 243); mometasone …

View Full Text


  • * See glossary.

  • For correspondence: Dr E O Meltzer, Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA. eomeltzer{at}

  • Source of funding: Schering-Plough Research Institute.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd